• Anti-DLL3 Antibody: Identity and Evidence Scope

  2026-10-17

  APExBIO describes F1968, also called Dragonfly patent anti-DLL3, as an unconjugated monoclonal IgG1 antibody directed against DLL3. The available documentation supports a reagent-level role in DLL3 protein detection and exploratory assay contexts, but it does not establish binding metrics, epitope, pathway modulation, disease-model effects, or clinical relevance.

• Pyridostatin: Mechanism and Evidence Boundaries

  2026-10-16

  APExBIO describes Pyridostatin, commonly supplied as Pyridostatin TFA, as a synthetic G-quadruplex DNA stabilizer associated with telomere dysfunction and growth inhibition in several human cell lines. The product description provides a useful mechanistic framework for telomere biology research and DNA secondary structure research, including a reported 18.5-fold selectivity for HT1080 over WI-38 cells. However, no identity-matched primary paper, assay definition, sample size, uncertainty estimate, or independent mechanistic validation is available here, so the claims should be treated as product-level documentation rather than established comparative evidence or clinical evidence.

• Val-Cit-PAB-OSBT: Evidence and Scope

  2026-10-16

  APExBIO identifies Val-Cit-PAB-OSBT as a chemically synthesized Val-Cit–PAB–OSBT linker associated with antibody-drug conjugate design. The supplied product description supports a conceptual account of cathepsin-sensitive cleavage and self-immolative release, but provides no identity-matched study, comparative data, release measurements, or evidence of ADC or therapeutic performance.

• Rozanolixizumab: Product and Mechanism Overview

  2026-10-15

  A source-attributed overview of the documented identity, FcRn-targeting mechanism, measurement scope, and evidence limitations of the Rozanolixizumab anti-FcRn antibody.

• 5-TAMRA: Identity, Mechanism, and Evidence

  2026-10-15

  APExBIO describes 5-TAMRA, also known as 5-carboxytetramethylrhodamine, as an orange-red fluorescent dye with reported excitation and emission maxima of 546 and 579 nm. These catalog claims establish a potential measurement role, but they do not constitute identity-matched evidence of assay performance, specificity, or superiority over alternatives.

• RGD Peptide C5357: What Is Documented

  2026-10-14

  The available APExBIO listing identifies RGD Peptide by the catalog number C5357, but provides no product description, molecular characterization, mechanism, assay data, or identity-matched research evidence. Accordingly, the defensible interpretation is limited to catalog-level provenance and clearly defined evidence boundaries.

• Developmental SSRI Exposure and Motivation in Mice

  2026-10-14

  A 2026 Columbia University dissertation reports that developmental fluoxetine exposure in mice was associated with persistent deficits in effortful motivation, while reward consumption and Pavlovian learning were comparatively preserved. Mu-opioid receptor interventions attenuated some motivational effects in this preclinical model, but the findings do not establish clinical implications for human antidepressant use.

• Electrical Stimulation and Nanoparticle Uptake

  2026-10-13

  A source-grounded overview of reported electrical-stimulation effects on magnetic nanoparticle uptake in cancer cells, with attention to mechanism, evidence strength, applicability limits, and the separate evidentiary status of Chlorpromazine HCl.

• What a Vitamin Docking Study Shows About COVID-19

  2026-10-13

  Eskandari’s 2022 computational study explored whether selected natural compounds might interact with SARS-CoV-2 entry and replication targets. Its results identify docking and molecular-dynamics signals—not demonstrated antiviral activity—and therefore remain hypothesis-generating rather than evidence of therapeutic effectiveness.

• PTEN mRNA in Trastuzumab-Resistance Research

  2026-10-12

  A preclinical study links nanoparticle delivery of PTEN mRNA with reduced trastuzumab resistance in breast-cancer models, but the findings do not establish clinical efficacy or validate any particular commercial mRNA product.

• DAPI Nuclear Stain: Identity and Evidence Scope

  2026-10-12

  APExBIO’s K2402 is documented as a ready-to-use DAPI fluorescent DNA-binding reagent intended for conceptual nuclear visualization and related endpoint assessments. No matched research paper was provided, so product-level claims should not be treated as independently validated evidence for viability or apoptosis.

• CLCC1 and Herpesvirus Nuclear Egress: An Overview

  2026-10-11

  A non-peer-reviewed preprint identifies the host protein CLCC1 as important for HSV-1 nuclear egress, while also reporting effects on nuclear pore insertion. The findings support a role in membrane and nuclear-envelope biology but do not establish CLCC1 as a direct fusion machine or provide evidence that Isoprinosine affects this pathway.

• EGTA in Calcium Signaling Research: Evidence and Limits

  2026-10-10

  EGTA, also known as egtazic acid, is a calcium-chelating research reagent used to examine calcium-dependent biology. This overview distinguishes supplier information from primary evidence, evaluates findings from a cardiac vagal neuron study, and explains why those results do not establish EGTA efficacy in neuroprotection, endothelial inflammation, or disease models.

• Caspofungin in Resistant Candida Research

  2026-10-09

  Caspofungin is a lipopeptide antifungal drug and echinocandin-class reference compound for studying fungal cell wall biosynthesis inhibition. This overview examines its research context through a 2021 study of ibrexafungerp and fluconazole-resistant Candida auris, where caspofungin served as a comparator in a murine invasive-candidiasis model. The evidence supports the relevance of glucan-synthesis inhibition, but it does not establish clinical effectiveness for caspofungin against every resistant Candida population or replace human clinical data.

• Calpain Inhibitor I, ALLN: Product Overview

  2026-10-09

  Calpain Inhibitor I, ALLN (SKU A2602) is an APExBIO research-use compound described as targeting calpain I/II and cathepsins B/L. No matched paper evidence was supplied, so application claims remain unverified here.

8135 records 1/543 page Next 12345 下5页 Last page